MARCELO ARAUJO QUEIROZ
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/43 - Laboratório de Medicina Nuclear, Hospital das Clínicas, Faculdade de Medicina
LIM/43 - Laboratório de Medicina Nuclear, Hospital das Clínicas, Faculdade de Medicina
3 resultados
Resultados de Busca
Agora exibindo 1 - 3 de 3
- External validation of a machine learning based algorithm to differentiate hepatic mucinous cystic neoplasms from benign hepatic cysts(2023) FURTADO, Felipe S. S.; BADENES-ROMERO, Alvaro; HESAMI, Mina; MOSTAFAVI, Leila; NAJMI, Zahra; QUEIROZ, Marcelo; MOJTAHED, Amirkasra; ANDERSON, Mark A. A.; CATALANO, Onofrio A. A.Purpose To externally validate an algorithm for non-invasive differentiation of hepatic mucinous cystic neoplasms (MCN) from benign hepatic cysts (BHC), which differ in management. Methods Patients with cystic liver lesions pathologically confirmed as MCN or BHC between January 2005 and March 2022 from multiple institutions were retrospectively included. Five readers (2 radiologists, 3 non-radiologist physicians) independently reviewed contrast-enhanced CT or MRI examinations before tissue sampling and applied the 3-feature classification algorithm described by Hardie et al. to differentiate between MCN and BHC, which had a reported accuracy of 93.5%. The classification was then compared to the pathology results. Interreader agreement between readers across different levels of experience was evaluated with Fleiss' Kappa. Results The final cohort included 159 patients, median age of 62 years (IQR [52.0, 70.0]), 66.7% female (106). Of all patients, 89.3% (142) had BHC, and the remaining 10.7% (17) had MCN on pathology. Agreement for class designation between the radiologists was almost perfect (Fleiss' Kappa 0.840, p < 0.001). The algorithm had an accuracy of 98.1% (95% CI [94.6%, 99.6%]), a positive predictive value of 100.0% (95% CI [76.8%, 100.0%]), a negative predictive value of 97.9% (95% CI [94.1%, 99.6%]), and an area under the receiver operator characteristic curve (AUC) of 0.911 (95% CI [0.818, 1.000]). Conclusion The evaluated algorithm showed similarly high diagnostic accuracy in our external, multi-institutional validation cohort. This 3-feature algorithm is easily and rapidly applied and its features are reproducible among radiologists, showing promise as a clinical decision support tool. [GRAPHICS] .
- An international expert opinion statement on the utility of PET/MR for imaging of skeletal metastases(2021) HUSSEINI, Jad S.; AMORIM, Barbara Juarez; TORRADO-CARVAJAL, Angel; PRABHU, Vinay; GROSHAR, David; UMUTLU, Lale; HERRMANN, Ken; CANAMAQUE, Lina Garcia; GARZON, Jose Ramon Garcia; PALMER, William E.; HEIDARI, Pedram; SHIH, Tiffany Ting-Fang; SOSNA, Jacob; MATUSHITA, Cristina; CERCI, Juliano; QUEIROZ, Marcelo; MUGLIA, Valdair Francisco; NOGUEIRA-BARBOSA, Marcello H.; BORRA, Ronald J. H.; KWEE, Thomas C.; GLAUDEMANS, Andor W. J. M.; EVANGELISTA, Laura; SALVATORE, Marco; CUOCOLO, Alberto; SORICELLI, Andrea; HEROLD, Christian; LAGHI, Andrea; MAYERHOEFER, Marius; MAHMOOD, Umar; CATANA, Ciprian; DALDRUP-LINK, Heike E.; ROSEN, Bruce; CATALANO, Onofrio A.Background MR is an important imaging modality for evaluating musculoskeletal malignancies owing to its high soft tissue contrast and its ability to acquire multiparametric information. PET provides quantitative molecular and physiologic information and is a critical tool in the diagnosis and staging of several malignancies. PET/MR, which can take advantage of its constituent modalities, is uniquely suited for evaluating skeletal metastases. We reviewed the current evidence of PET/MR in assessing for skeletal metastases and provided recommendations for its use. Methods We searched for the peer reviewed literature related to the usage of PET/MR in the settings of osseous metastases. In addition, expert opinions, practices, and protocols of major research institutions performing research on PET/MR of skeletal metastases were considered. Results Peer-reviewed published literature was included. Nuclear medicine and radiology experts, including those from 13 major PET/MR centers, shared the gained expertise on PET/MR use for evaluating skeletal metastases and contributed to a consensus expert opinion statement. [18F]-FDG and non [18F]-FDG PET/MR may provide key advantages over PET/CT in the evaluation for osseous metastases in several primary malignancies. Conclusion PET/MR should be considered for staging of malignancies where there is a high likelihood of osseous metastatic disease based on the characteristics of the primary malignancy, hight clinical suspicious and in case, where the presence of osseous metastases will have an impact on patient management. Appropriate choice of tumor-specific radiopharmaceuticals, as well as stringent adherence to PET and MR protocols, should be employed.
- Radiopharmaceuticals and contrast agents(2022) KAKO, B.; ROMERO, A. B.; QUEIROZ, M. A.; GALGANO, S. J.; CARAVAN, P.; ESFAHANI, S. A.PET/MRI is the most advanced imaging technology available for clinical use. Its enormous potential can be unleashed only when both PET and MRI are properly and complementarily used. This starts with the choice of the most appropriate PET radiopharmaceutical and MR contrast agent for each specific clinical scenario and continues with building the most tailored PET/MRI protocol that fits the specific properties of the chosen radiopharmaceutical along with the potential additional information provided by the MRI contrast agent. This chapter provides a clinical and practical perspective of the most relevant and commonly used radiopharmaceuticals and MR contrast agents. © 2023 Elsevier Inc. All rights reserved.